4 completed, 2 unknown, 1 recruiting, 1 terminated. 8 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Unknown 2, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Surface-Active Agents: new trials by email Literature Review of Surface-Active Agents trials Research Report on Surface-Active Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy) - Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Phase 1 / Phase 2 | Recruiting | enGene, Inc. | 350 | 2021-04-22 | 2026-08-07 |
| The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19) Lucinactant - COVID-19, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Phase 2 | Completed | Windtree Therapeutics | 20 | 2021-01-05 | 2023-06-23 |
| London's Exogenous Surfactant Study for COVID19 Bovine Lipid Extract Surfactant - ARDS, Human, COVID-19 | Phase 1 / Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 20 | 2020-11-23 | 2021-11-11 |
| Aerosolized Surfactant in Neonatal RDS Surfactant - Respiratory Distress Syndrome, Newborn | Phase 1 / Phase 2 | Completed | Sood, Beena G., MD, MS | 159 | 2014-12-01 | 2021-08-25 |
| Minimally Invasive Surfactant Therapy Followed by CPAP (MISTCPAP) in Preterm Infants With RDS Surfactant - Respiratory Distress Syndrome | Phase 2 | Unknown | China Medical University Hospital | 60 | 2012-02-01 | 2012-11-08 |
| Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old Lucinactant, Sham Comparator - Acute Hypoxemic Respiratory Failure | Phase 2 | Completed | Windtree Therapeutics | 165 | 2007-06-01 | 2012-05-03 |
| SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants. Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo - Respiratory Distress Syndrome, Newborn, Premature Birth | Phase 2 | Terminated | Windtree Therapeutics | 136 | 2005-02-01 | 2012-06-13 |
| The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot Study Surfactant (calfactant) - Lung Transplantation, Primary Graft Dysfunction | Phase 2 / Phase 3 | Unknown | Rabin Medical Center | 42 | 2005-01-01 | 2007-07-25 |
Respiratory Distress Syndrome (3) · COVID-19 (2) · Respiratory Distress Syndrome, Newborn (2) · Acute Lung Injury (1) · Bronchopulmonary Dysplasia (1) · Carcinoma in Situ (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Premature Birth (1) · Primary Graft Dysfunction (1) · Respiratory Insufficiency (1) · Urinary Bladder Neoplasms (1)
Windtree Therapeutics (3) · China Medical University Hospital (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Rabin Medical Center (1) · Sood, Beena G., MD, MS (1) · enGene, Inc. (1)
United States (5) · Canada (2) · Taiwan (2) · Argentina (1) · Australia (1) · Chile (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Adrienne Randolph, MD (1) · Bai-Horng Su, MD, PhD (1) · Beena G. Sood, MD, MS (1) · Carlos Guardia, MD (1) · Christine Tosone, Ms, RAC (1) · Hsieh-Yu Lin, MD (1) · Jim Lewis, MD (1) · Matthew M Laughon, MD, MPH (1) · MordechaI R Kramer, Prof (1) · Neal Thomas, MD (1) · Steve G Simonson, MD (1) · Yuh-Chin T Huang, MD, MHS (1)
PMID 19117865, PMID 22791092, PMID 33338661, PMID 34337553, PMID 35474746, PMID 42536986